Difference in the efficacy of the modified-vaccinia Ankara vaccine as pre-exposure and post-exposure prophylaxis against sexual transmission of monkeypox virus clade IIb in non-human primates
Authors:
- Francis RelouzatFRFrancis Relouzat
- Nathalie BosquetNBNathalie Bosquet
- Benoit DelacheBDBenoit Delache
Preprint
- 30 October 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
The monkeypox virus (MPXV) outbreak of 2022 caused a human disease with unusual epidemiological and clinical features, notably an increase in human-to-human transmission through sexual contact, predominantly among men who have sex with men (MSM). This evolution underscores the need to reassess prevention and control strategies in the context of a sexually transmitted disease. Here, we show that rectal challenge of cynomolgus macaques with a 2022 clade IIb MPXV isolate mimics sexual transmission, leading to rectal infection, with systemic and male genital tract dissemination and seminal fluid shedding. Vaccination with modified-vaccinia Ankara (MVA) protected the macaques from subsequent rectal MPXV challenge. However, MVA failed to prevent the disease when administered four days post-exposure to MPXV. These findings have a critical impact on outbreak management and highlight the importance of reevaluating MVA post-exposure prophylaxis protocols.Keywords
All Related Versions
This publication has 33 references indexed in Scilit:
- Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023Vaccine, 2024
- Description of mpox reinfection by whole genome sequencingInternational Journal of Infectious Diseases, 2023
- Mpox infection protects against re-challenge in rhesus macaquesCell, 2023
- Mpox in people with advanced HIV infection: a global case seriesThe Lancet, 2023
- Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case seriesThe Lancet, 2022
- Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccinationVaccine, 2012
- Real-time PCR assays for the specific detection of monkeypox virus West African and Congo Basin strain DNAJournal of Virological Methods, 2010
- Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challengeVaccine, 2009
- Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccineVirology, 2008
- Standardization of a neutralizing anti-vaccinia antibodies titration method: an essential step for titration of vaccinia immunoglobulins and smallpox vaccines evaluationJournal of Clinical Virology, 2005